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Poly(ethylene oxide)-poly(propylene oxide) block co-polymers
(Pluronic or ‘poloxamer’) have recently been used in formulations
to treat drug-resistant cancers (Alakhov et al, 1996; Batrakova
et al, 1996; Venne et al, 1996). Following validation using in vitro
and in vivo models, a formulation that contains doxorubicin and
Pluronic mixture (L61 and F127), SP1049C, is currently under-
going Phase I clinical trials (Alakhov et al, 1999). Experimental
studies have demonstrated that Pluronic block copolymers sensi-
tize MDR cells, resulting in an increase in the cytotoxic activity of
anthracyclines and other cytotoxic drugs by 2–3 orders of magni-
tude (Alakhov et al, 1996; Venne et al, 1996). This finding is
important in light of the major problem of drug resistance to anti-
neoplastic agents, which severely limits the chemotherapy of
many cancer tumours (Goldstein et al, 1992). Tumours with the
MDR phenotype have been widely recognized as one of the most
difficult types to treat. MDR cells overexpress efflux transporters
belonging to a superfamily of ATP-binding cassette (ABC)
proteins, such as P-glycoprotein (Pgp) and multidrug resistance-
associated proteins (MRPs) that pump drugs out of a cell (Zaman
et al, 1995; Hayes and Pulford, 1995). The glutathione/glutathione
S-transferase detoxification system is frequently activated in MDR
cells contributing to drug resistance (Altan et al, 1998). MRP acts
in concert with this system, providing for the efflux of glutathione
conjugates of xenobiotics from the cells (Zaman et al, 1995).
Another impediment to treatment, which is present in MDR cells,
involves the sequestration of drugs within cytoplasmic vesicles,
followed by extrusion of the drug from the cell (Altan et al, 1998).
Drug sequestration in MDR cells is achieved through the 
maintenance of abnormally elevated pH gradients across organelle
membranes by the activity of H+-ATPase, an ATP-dependent
pump (Benderra et al, 1998). Energy-dependent processes associ-
ated with the above drug resistance mechanisms impose higher
energy requirements upon the MDR cells, which might render
these cells more sensitive to energy-depleting agents as opposed to
the wild type cells, which have lower energy requirements (Kaplan
et al, 1990). This paper, for the first time, demonstrates that
Pluronic P85 (P85) induces a dramatic reduction in ATP levels
selectively in MDR cells, while non-MDR cells are not responsive
to this block copolymer in this manner. Energy depletion induced
by P85 correlates with its observed sensitization effect in MDR
cells with respect to doxorubicin. This provides a pivotal new
insight regarding the mechanism of potentiation of cytotoxicity of
select drugs by Pluronic block copolymers in MDR cells. 
MATERIALS AND METHODS 
Drugs 
Doxorubicin was purchased from Sigma Chemical Co. (St Louis,
MO, USA) and P85 (lot No. WPOP-587A) was provided by BASF
Corp. (Parispany, NJ, USA). Doxorubicin/P85 was prepared by
adding doxorubicin to the culture medium containing various
concentrations of P85. 
Cell culture 
The human epithelial cell line KB (ATCC CCL-17) and its MDR
subline, KBv, derived by selection with vinblastine, were kindly
provided by Dr DW Miller (University of Nebraska Medical
Center, Omaha, NE, USA). These cells were cultured in DMEM
with 10% FBS, 10 mM HEPES and penicillin/streptomycin; KBv
cultures were supplemented with 1 µ g/ml vinblastine (Faulding
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epithelium cell line, Caco-2, was kindly provided by RT Borchardt
(University of Kansas, Lawrence, KS, USA) and was cultured in
the media mentioned earlier. The murine myoblast line, C2C12
(ATCC CRL-1772), was kindly provided by P Lemieux (Supratek
Pharma Inc., Montreal, PQ, Canada) and was cultured in the media
mentioned earlier. The human breast carcinoma cell line MCF-7
(ATCC HT-B22) and its MDR subline MCF-7/ADR, derived by
selection with doxorubicin, were kindly presented by YL Lee
(William Beaumont Hospital, Royal Oak, Ml, USA). These cells
were cultured in the same media mentioned earlier, except HEPES
was increased to 1%, MCF-7/ADR cultures were supplemented
with 10 ng/ml doxorubicin (Gensia Laboratories LTD, Irvine, CA,
USA). The porcine kidney epithelial cell line, LLC-PK1 (ATCC
CL-101) and its MDR subline, LLC-MDR1, derived by transfec-
tion with human MDR1 in the laboratory of Dr Piet Borst (The
Netherlands Cancer Institute, Amsterdam, Netherlands), were
obtained from Dr Erin Schuetz (St Jude Hospital, Memphis, TN,
USA). These cells were cultured in Medium 199 with 10% FBS,
10 mM HEPES and penicillin/streptomycin; LLC-MDR1 cultures
were supplemented with 640 nmol/ml vincristine (SP Pharmaceuti-
cals Inc, Albuquerque, NM, USA). Human umbilical vein
endothelial cells (HUVECs) were purchased from BioWhittaker
(San Diego, CA, USA) and cultured in EGM-2 media
(BioWhittaker). Bovine brain microvessel endothelial cells
(BBMECs) were isolated and cultured as described previously
(Fontaine, 1996). All other tissue culture reagents were obtained
from Gibco Life Technologies, Inc. (Grand Island, NY, USA). The
cells were seeded at a density of 25 000 cells/cm2 into 24-well
plates and were used for accumulation studies after reaching
confluency (typically within 6–7 days). 
Western blot analysis 
Identification of Pgp was done using the immunoblot technique
described previously (Miller et al, 1996). The monoclonal anti-
bodies used for Pgp were C219 (Dako Corp., Carpinteria, CA,
USA). They were used at a dilution of 1:100. The secondary
horseradish peroxide anti-mouse Ig antibodies (dilution 1:1500)
were purchased from Amersham Life Sciences (Cleveland, OH,
USA). The specific protein bands were visualized using a chemilu-
minescence kit (Pierce, Rockford, IL, USA). 
Determination of intracellular ATP 
Cell monolayers were grown in 24-well plates until confluent. On
the day of treatment, the medium was removed and replaced
with assay buffer, which is composed of the following: NaCl
(122 mM), NaHCO3 (25 mM), glucose (10 mM), KCl (3 mM),
MgSO4 (1.2 mM), K2HPO4 (0.4 mM), CaCl2 (1.4 mM) and
HEPES (10 mM). Cells were equilibrated in this buffer for 30 min,
then the assay buffer was removed and replaced with P85 treat-
ment solutions (0.0001–5% wt.) in assay buffer. Cells were
exposed to P85 for 2 h then washed twice with ice-cold PBS and
solubilized in a 1% solution of Triton X-100 in PBS. The lysates
were collected and frozen immediately (–20˚C) for subsequent
ATP quantification (conducted within 24 h following the sample
collection). ATP was determined as previously described using a
luciferin/luciferase assay (Garewal et al, 1986). For this purpose,
100 µ L aliquots of lysate were mixed with 100 µ L of ATP assay
mix (# FL-AAM, Sigma). Light emission was measured with a
Turner Designs luminometer (model 20/20). Data were acquired
as relative light units integrated over 20 s for samples and for stan-
dard calibration curves obtained using ATP standard (# FL-AAS,
Sigma). ATP levels were normalized for protein content, which
was assayed by using the Pierce BCA assay kit. Each data point
represented the mean + SEM of a minimum of 4 replicates. 
Cytotoxicity assay 
Cells were seeded in 96-well plates at a density of 5000 cells per
well and allowed to attach overnight. Cells were exposed to
doxorubicin alone or doxorubicin/P85 solutions (from 0.0001–5%
P85) for 2 h at 37˚C, 5% CO2. Cells were washed three times with
the fresh medium and cultured for 3 d in the medium in the
absence of the drug and P85. The cytotoxic activity of doxorubicin
was then evaluated using a standard MTT assay (Ferrari et al,
1990). The absorbency at λ = 450 nm was determined using a
microKinetics Reader BT 2000. Each concentration point was
repeated in eight wells. SEM values were less than 10%. 
Rhodamine 123 (R123) accumulation 
R123 accumulation in cells was studied as previously described
(Batrakova et al, 1999). 
Pgp ATPase assay 
Membranes, expressing human Pgp (Gentest Co., MA, USA) were
used to evaluate the effects of P85 on Pgp ATPase activity. A 0.06
ml reaction mixture containing 40 µ g membranes, 20 µ l assay
buffer, with or 0.1% P85, were added to buffer solutions,
containing 3–5 mM MgATP, 50 mM Tris-MES, 2 mM EGTA,
50 mM KCl, 2 mM dithiothreitol, and 5 mM sodium azide, and
incubated at 37˚C for 20 min. An identical reaction mixture
containing 100 µ M sodium orthovanadate was assayed in parallel.
The reactions were stopped by the addition of 30 µ l of 10%
SDS with antifoam A. Aliquots (200 µ l) of ammonium molybdate
in 15 mM zinc acetate: 10% ascorbic acid (1:4) were added to each
sample and incubated for an additional 20 min at 37˚C. The liber-
ation of inorganic phosphate was detected by its absorbance at
630 nm and quantitated by comparing the absorbance to a
phosphate standard curve (Druekes et al, 1995). 
RESULTS 
Concentration dependency of P85 effects on ATP levels
in MDR and non-MDR cells 
To examine the effects of P85 on intracellular ATP levels, resistant
(MCF-7/ADR) and sensitive (MCF-7) cells were exposed to this
block copolymer at various concentrations (without drug) for 2 h.
After that, cells were lysed and ATP was quantified. Figure 1A
presents the ATP levels observed in resistant and sensitive cells
following the treatment with P85. In the resistant cells, exposure to
low concentrations of Pluronic (ca. 0.05% wt.) resulted in a
decrease in the ATP level to 3.8% of the initial value. In contrast,
in the sensitive cells, ATP levels did not drop until much higher
concentrations of the block copolymer (ca. 5% wt.) were reached.
At these P85 concentrations, the ATP levels in the sensitive cells
decreased to 15% of the initial value. Therefore, exposure to low
concentrations of P85 causes a selective decrease in ATP levels
(energy depletion) in MDR cells but not in the sensitive cells. 
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To determine the kinetics of P85-induced energy depletion, the
MCF-7/ADR cells were exposed to the block copolymer for
various time intervals and the ATP levels were determined as
described in the previous section. The data are presented in Table 1.
Rapid energy depletion was observed during first 15–30 min of
cell exposure to P85. After that, ATP levels remained low and only
slightly decreased during 2-hour exposure to the block copolymer.
Similar time dependence of ATP depletion was observed in sensi-
tive MCF-7 cells exposed to 5% P85 (a dose that causes energy
depletion in these cells). 
Energy restoration following P85 exposure 
The ability of the cells to restore ATP levels following removal of
P85 from the culture medium was tested in the following experi-
ment. MCF-7/ADR cells were exposed to 0.1% P85 for 2 h, to
induce reduced ATP levels, then the P85-containing supernatants
were removed and cells were cultured in the copolymer-free media
for various time periods. Measurements of the ATP levels at various
timepoints after removal of P85 suggested that ATP levels restored
after 15 h, and then maintained at the pre-treatment levels for at least
70 h (Table 2). In a similar experiment, sensitive MCF-7 cells were
exposed to 5% P85 and then cultured in the absence of P85 for
various time periods to examine energy restoration. In this case, ATP
levels were also restored after the 15-hour interval (Table 2). 
Absence of cytotoxic effects of P85 
To examine whether exposure to Pluronic affects the viability of
cells, both resistant and sensitive cells were exposed to various
doses of P85 (without drug) for 2 h. After removal of the P85, cells
were cultured in the block-copolymer free media for 72 h and
cytotoxicity was determined using MTT assay. As in seen in
Figure 1, 2-hour exposure to P85 did not induce significant cyto-
toxic effects in either resistant or sensitive cells over the range of
concentrations tested (from 0.0001 to 5%). 
Responsiveness of various cells to P85-induced energy
depletion 
To examine the correlation of the P85-induced energy depletion
with the expression of the drug efflux transporters in the cells, this
study compared the effects of the block copolymer on ATP levels
in several cell types that either express Pgp, or do not express Pgp.
First, the cell panel used in this study included pairs of resistant
and sensitive cancer cell lines: MCF-7/ADR and MCF-7 as well as
KBv and KB. Second, the panel included cells with intrinsic Pgp
expression, Caco-2 and BBMECs, as well as Pgp-negative cells,
human umbilical vein endothelial cells (HUVECs) and C2C12
myoblasts. Finally, this panel included porcine kidney cells, LLC-
MDR1, stably expressing the MDR1 gene, and its counterpart,
LLC-PK1, with low endogenous Pgp levels (Evers et al, 1996).
The levels of expression of Pgp in the cells used in this study were
confirmed by a Western blot analysis (Figure 2). In this study the
drug-selected MDR and MDR1-transfected lines (MCF-7/ADR,
KBv, LLC-MDR1) exhibited very high levels of Pgp. Pgp was also
present in BBMECs and Caco-2 cells, although its amounts were
much lower than in drug-selected and -transfected MDR cells. All
sensitive cell lines revealed much lower levels of endogenous Pgp
compared to the MDR cells. The functional activity of Pgp was
validated using R123 as a Pgp-sensitive probe (Lee et al, 1994). 
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Figure 1 Effects of P85 on (A) intracellular ATP levels; and (B) cell survival
in resistant MCF-7/ADR (filled circles) and sensitive MCF-7 (empty circles)
cells
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Table 1 Kinetics of ATP depletion in MCF-7/ADR cells in the presence of
0.1% P85 
Time of exposure (min) ATPa, nmol/mg protein 
0 300 + 32 
15 61.4 + 4.6 
30 40.2 + 7.2 
60 33.4 + 11 
90 26.2 + 0.9 
120 25.5 + 0.6 
aMean + SEM (n = 4). 
Table 2 Intracellular ATP levels before and after treatment of MCF-7/ADR
or MCF-7 cells with P85a
Time of measurement of ATP level ATP, nmol/mg proteinb
MCF-7/ADR MCF-7 
Before P85 treatment 302 + 21 29.0 + 1.4 
Immediately after 2 h exposure to P85 15.3 + 2.3 2.4 + 0.34 
After P85 removal: 
4 h 21.2 + 2.7 14.9 + 1.5 
15 h 402 + 13 40.0 + 1.9 
39 h 325 + 31 22.3 + 1.1 
48 h 265 + 52 27.6 + 2.4 
70 h 301 + 28 28.5 + 1.5 
aCells were exposed to 0.1% (MCF-7/ADR) or 5% (MCF-7) P85 and then
incubated for various time periods in the copolymer-free culture media. 
bMean + SEM (n = 4). In the energy depletion study, the cells were exposed for 2 h to
various concentrations of P85 and then ATP levels were deter-
mined as described earlier. The effective concentrations of P85
that induced a 50% decrease in ATP levels in the cells (EC50), as
determined from the dose-response curves are presented in Table 3.
This table also presents the relative responsiveness of the Pgp-
expressing cells compared to their counterparts with low levels of
Pgp expression. While there were significant differences in the
initial ATP levels observed between various cell lines and these
differences were very well reproduced in repeated experiments
(not shown in Table 3), the responsiveness of the cells to P85 did
not appear to correlate with the amount of ATP available in these
cells. Conversely, as is seen in Table 3, the responsiveness of the
cells to Pluronic correlated with expression of Pgp in these cells.
Specifically, energy depletion was observed in the resistant cell
lines MCF-7/ADR and KBv, but not in the sensitive parental cells
lines MCF-7 and KB. Likewise, Caco-2 and BBMECs, which
have functionally active Pgp (Batrakova et al, 1998), responded to
P85 at lower concentrations of the block copolymer than the
HUVECs and C2C12 cells, which have low levels of Pgp expres-
sion by Western blot and functional assays. Finally, transfected
LLC-MDR1 cells, overexpressing Pgp, were highly responsive to
P85 treatment, while their non-Pgp counterparts were much less
responsive to such treatment. Based on the results of this study, it
appears that the expression of drug efflux proteins is one factor
that renders cellular metabolism responsive to treatment with P85.
Among cells with the lowest level of Pgp expression, the highest
responsiveness to P85 treatment was observed for HUVECs which
exhibited an EC50 value of 0.0675% (Table 3). Although these cell
lines were characterized as Pgp negative (Iwahana et al, 1998),
it might express some other transport systems that could play
a similar role as Pgp, resulting in the response to the block
copolymer. Furthermore, Caco-2 cells, which exhibited a rela-
tively small amount of Pgp in the Western blot analysis compared
to the drug-selected and MDR1-transfected cells, were very
responsive to P85 in the energy depletion study. Once again Caco-
2 cells may have some other factors present, besides the Pgp efflux
system, which determine their high responsiveness to the block
copolymer. 
Selective energy depletion by metabolic inhibitors 
To compare the effects of P85 and known metabolic inhibitors,
MCF-7/ADR and MCF-7 cells were exposed for 2 h to various
inhibitors, rotenone, sodium aside, and 2-deoxyglucose as well as
P85. After that the intracellular ATP levels were measured and the
EC50 values were determined from the dose-response curves as
described in the previous section. Table 4 shows the results of this
experiment. All metabolic inhibitors examined appeared to induce
selective energy depletion in MDR cells when compared to non-
MDR cells. The selectivity of these agents with respect to MDR
cells varied from about 10 to about 200 times (as determined by
the values of the relative responsiveness presented in the table). 
Relationship between energy depletion and cytotoxicity 
The effect of P85 on the cytotoxicity of doxorubicin was deter-
mined using drug-selected and MDR1-transfected, resistant cells
(MCF-7/ADR, KBv, LLC-MDR1) as well as their non-MDR
counterparts (MCF-7, KB, LLC-PK1). The resulting IC50 values of
doxorubicin determined in these cell lines without and with 0.1%
P85 are presented in Table 5. Comparison of these data with the
ATP depletion studies presented in Table 3, provides initial
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Figure 2 Western blot analysis of Pgp in various cell lines: (1) MCF-7, 
(2) MCF-7/ADR, (3) Kb, (4) Kbv, (5) HUVECs, (6) Caco-2, (7) BBMECs, 
(8) LLC-PK1, (9) LLC-MDR1, (10) C2C12. A total of 25 µ g of protein was
loaded onto 7.5% polyacrylamide gels. Primary antibodies for Pgp (C219) were
used at dilution of 1:100; secondary antibody was used at a dilution of 1:1500.
The protein was detected using chemiluminescence 
Table 3 Effects of P85 on ATP levels in various cells following 2-hour exposure to the block copolymer 
Cells Pgp or MRP  Initial ATP levels  EC50 (%) Relative responsiveness 
overexpression nmol/mg proteina to P85b
MCF-7 No 30 + 1.5 2.25 –
MCF-7/ADR Pgp 300 + 20 0.009 250c
KB No 1 + 0.01 0.675 –
KBv Pgp 4 + 0.1 0.036 19d
C2C12 No 15 + 1.4 4.5 –
HUVECs No 40 + 4.9 0.0675 –
Caco-2 Pgp 5.5 + 0.4 0.00067 6670e
BBMECs Pgp 1.6 + 0.04 0.018 250d
LLC-PK1 No 61 + 6.9 0.45 –
LLC-MDR1 Pgp 79 + 1.7 0.0045 100f
aMean + SEM (n = 4). bCalculated as the ratio of EC50 of non-Pgp cells to EC50 of corresponding Pgp expressing cells.
cCompared to MCF-7 cells. dCompared to KB cells. eCompared to C2C12 cells. fCompared to LLC-PK1 cells. 
Table 4 Comparison of the effects of P85 and metabolic inhibitors on ATP
levels in MDR and non-MDR cells 
Agent
EC50,a µ M Relative
MCF-7 MCF-7/ADR
responsivenessb
P85 5000 20 250 
Rotenone 0.03 0.0008 37 
Sodium aside 100 000 10 000 10 
2-deoxyglucose 200 1 200 
aMean + SEM (n = 4). bCalculated as the ratio of EC50 of MCF-7 cells to EC50
of MCF-7/ADR cells. evidence of the relationship between the sensitization effect and
the energy depletion phenomenon. 
This relationship is further illustrated by the dose-dependent
studies shown in Figure 3. Figure 3A presents the IC50 in the resis-
tant cells, KBv upon co-administration of doxorubicin with
various doses of P85. The data show that P85 potentiates the cyto-
toxic activity of doxorubicin with respect to MDR cells (IC50
decreases). This effect was registered at approximately the same
doses of P85 that cause energy depletion in MDR cells (also
shown in Figure 3A). In contrast, treatment with the same or
higher doses of P85 (up to at least 1%) did not result in a similar
potentiation of cytotoxicity in the non-MDR line, KB (data not
shown). 
Figure 3B summarizes the data of Figure 3A on the doxorubicin
cytotoxicity and energy depletion studies in resistant KBv cells.
This presents the relationship between (1) the ATP levels deter-
mined after exposure of the cells to various concentrations of P85
and (2) the IC50 of doxorubicin determined in the presence of the
same concentrations of P85. These studies suggest that the effect
of P85 on the ATP levels in MDR cells correlates well with the
sensitization effect of this block copolymer in MDR cells. The
lower the ATP level is, the more cytotoxic the drug becomes. Very
similar results were obtained using another resistant cell line,
MCF-7/ADR (data not shown). 
Energy supplementation abolishes sensitization of
resistant cells by P85 
The relationship between P85-induced changes in ATP levels and
the sensitization effect in the resistant cells was further examined
using KBv cells. This cell line was exposed for 2 h to doxorubicin
alone or doxorubicin formulated with 0.1% P85. In an attempt to
bypass Pluronic-induced energy depletion, one more treatment
group was also included in this study, in which doxorubicin/P85 was
supplemented with 50 µ M ATP and 10–5 M dodecylamine, as a
permeabilizing agent. As reported previously by Slepnev et al
(1992), treatment of the cells with dodecylamine in combination
with P85 allows transport of ATP into the cells from the extracellular
media. The role of dodecylamine in this system is to provide for the
positive charge that enhances binding of the ATP molecule with the
block copolymer aggregates. These aggregates containing adsorbed
ATP subsequently are internalized within the cells (Slepnev et al,
1992). Following exposure of the cells to doxorubicin solutions,
drug-induced cytotoxicity was determined. In a parallel study, the
KBv cells were exposed for 2 h to the same treatment solutions,
without doxorubicin, and intracellular ATP levels were determined.
As is seen in Figure 4A, in the absence of ATP in the extracellular
media, P85 induced a substantial decrease in ATP in KBv cells. The
cytotoxic activity of doxorubicin was also enhanced in this case,
resulting in ca. 83-fold decrease in IC50 for the doxorubicin/P85
formulation compared to the IC50 of the free drug. However, when
the external media was supplemented with ATP and dodecylamine,
both the energy depletion and sensitization effects of P85 were
considerably reduced. In this case, the IC50 value of doxorubicin
formulated with Pluronic was only 5.5 times less than the IC50 of free
doxorubicin. No effect from the addition of extracellular ATP and
dodecylamine on the IC50 of the drug was observed in the absence
of P85 (data not shown). To validate the results of this study using
a drug-selected MDR cell line, KBv, the same experiment was
repeated with the MDR1-transfected cell line, LLC-MDR1. The
result was essentially the same (Figure 4B). P85 sensitized the cells,
decreasing the IC50 of the drug by over 100-fold. The intracellular
ATP levels were also decreased as already discussed. The treatment
of the cells with the energy supplementation system in this case
Energy depletion in MDR cells by Pluronic P85 1991
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Table 5 Effects of P85 on IC50 of doxorubicin in drug-selected 
and -transfected MDR cell lines as well as the non-MDR cells 
Relative  
Cells IC50, µ g/mla responsiveness
Assay buffer 0.1% P85  to P85b
MCF-7/ADR 900 ± 5 4.5 ± 0.2 200 
MCF-7 2.0 ± 0.1 2.0 ± 0.1 1 
KBv 5300 ± 21 12.6 ± 0.1 420 
KB 1.00 ± 0.03 1.00 ± 0.03 1 
LLC-MDR1 200 ± 11 0.80 ± 0.04 250 
LLC-PK1 2.0 ± 0.1 2.0 ± 0.1 1 
aMean ± SEM (n = 4). bCalculated as the ratio of IC50 of control non-treated
cell to IC50 of treated with most effective concentration of P85. 
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Figure 3 (A) Effects of P85 on IC50 of doxorubicin (filled symbols) and ATP
intracellular levels (empty symbols) in KBv cells. (B) Relationship between
the P85-induced changes in IC50 of doxorubicin and ATP levels in KBv cells.
Cells were exposed to treatment solutions for 2 hresulted in the intracellular ATP levels that exceeded the initial
values. The increase in the ATP levels in the presence of the energy
supplementation system was accompanied by practically complete
abolishment of the sensitization effect of the block copolymer.
Overall, based on these studies, it appears that there is a direct rela-
tionship between the levels of ATP and sensitization of resistant cells
with respect to doxorubicin by P85. 
Energy depletion by metabolic inhibitor sensitizes
resistant cells 
This relationship was further validated by comparing the effect of
P85 with that of the combination of metabolic inhibitors, 
2-deoxyglucose and sodium azide, in KBv and LLC-MDR1 cells.
For this purpose, additional treatment groups were included in the
studies discussed in the previous section. In these groups the cells
were treated by exposure to a mixture of 2-deoxyglucose (50
mM) and sodium azide (150 µ M). The intracellular ATP levels
and cytotoxicity of doxorubicin following this treatment were
determined as described earlier. As is seen in the figures, expo-
sure of both cell lines, KBv (Figure 4A) and LLC-MDR1
(Figure 4B) to the 2-deoxyglucose and sodium azide mixture
resulted in a considerable decrease in ATP, which was comparable
in magnitude to the effect of P85 observed in these cells.
Furthermore, the decrease in ATP levels induced by the metabolic
inhibitors was also accompanied by an increase in the sensitivity
of the cells to the drug. It is noteworthy that in the KBv cells, the
effect of the metabolic inhibitor on the cytotoxicity of doxoru-
bicin has the same magnitude as the sensitization effect of P85 in
these cells (Figure 4A). Conversely, in LLC-MDR1 (Figure 4B),
the metabolic inhibitors appeared to be much less potent than the
block copolymer and induced only a 10-fold decrease in IC50 of
doxorubicin compared to over a 100-fold effect of P85 in these
cells. Overall, the studies reported in this section suggest that
inhibition of metabolism in the resistant cells leads to the sensiti-
zation of the cells with respect to antineoplastic agent cytotoxic
action. 
Comparison of different Pluronic copolymers 
Figure 5 presents the effects of two Pluronic copolymers, L61 and
F127 on the intracellular ATP levels in the MDR cell line MCF-
7/ADR (panel A) and LLC-MDR1 (panel B). Both copolymers
consist of ethylene oxide (EO) and propylene oxide (PO) seg-
ments arranged in a basic structure: EOa-POb-EOa, but they differ
in the overall lengths and weight proportion of these segments.
Previous study demonstrated that L61 is a potent sensitizing agent
for MDR cells, while F127 is inactive in this respect (Batrakova
et al, 1999). As seen in Figure 5, exposure of both cell lines to low
concentrations of L61 (ca. 0.01% wt.) resulted in a decrease in
ATP levels. In contrast, in the F127 treatment groups, ATP levels
did not decrease until very high concentrations of the block
copolymer (10% wt.) were reached. This provides further evid-
ence supporting the relationship between the ability of Pluronic
block copolymers to decrease ATP levels and sensitize MDR
cells. 
Relationship between Pgp inhibition and energy
depletion 
The fluorescent dye, R123 was used in this work to examine the
functional activity of the Pgp efflux pump (Lee et al, 1994).
Figure 6 presents the accumulation of R123 in the Pgp
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Figure 4 Intracellular ATP levels (empty bars) and doxorubicin cytotoxicity (IC50, filled dots) modulated by various agents in (A) KBv cells and (B) LLC-MDR1
cells. ATP levels (means + SEM, n = 4) were determined after exposure of the cells for 2 h to the following treatment solutions: (1) copolymer-free media, 
(2) P85 (0.1%), (3) P85 (0.1%) in the presence of extracellular ATP (50 µ M) and dodecylamine (10–5 M), (4) sodium azide (150 µ M) and 2-deoxyglucose 
(50 mM). For cytotoxicity studies, the corresponding treatment solutions also contained various concentrations of doxorubicin, and IC50 values were determined
using a standard MTT assay following 3-day culturing of the cells in the drug-free mediumoverexpressing cells, KBv in the presence of various doses of
P85. The data show that at lower concentrations of from
0.001–0.1%, P85 increases the accumulation of the probe in the
cells. According to the previous studies, this effect is due to the
inhibition of the Pgp efflux system (Batrakova et al, 1999; Evers
et al, 2000). At higher concentrations of P85 (0.1–5%) the R123
levels decrease. The effect of high P85 concentrations is believed
to be due to incorporation of the probe in the P85 micelles,
resulting in the decrease in the amounts of the free probe avail-
able for diffusion into the cells (Batrakova et al, 1999). Figure 6
also presents the data on the P85-induced energy depletion in
MCF-7/ADR cells. It is seen from this data that at lower concen-
trations of P85 (0.001–0.1% P85), when the transport of the
probe is not impeded by its incorporation in the P85 micelles,
rhodamine accumulations change inversely to the ATP changes.
This suggests that the lower the ATP level is, the less active the
Pgp efflux system becomes. The same results were obtained
using the KBv cell line. 
Energy supplementation activates Pgp efflux 
The following study evaluated whether energy supplementation
can restore the Pgp efflux function in the resistant cells in the pres-
ence of P85. The experiment was conducted using MCF-7/ADR
cells analogously to the energy supplementation described earlier.
Rhodamine accumulation in MCF-7/ADR cells was examined for
five treatment groups: 
1. The probe in the assay buffer 
2. The probe in 0.1% P85 solution 
3. The probe in 0.1% P85 solution supplemented with a mixture
of 50 µ M ATP and 10–5 M dodecylamine 
4. The probe in 0.1% P85 solution and 10–5 M dodecylamine 
5. The probe in 10–5 M dodecylamine. 
In a parallel study, intracellular ATP levels were also determined
following exposure of the MCF-7/ADR cells to the corresponding
treatment solutions (without probe). As is seen in Figure 7A, there
was an inverse correlation between the R123 uptake and ATP
intracellular levels. First, in the presence of P85, the ATP level was
decreased while the probe accumulation was increased compared
to the assay buffer controls. Second, when the P85 treatment was
supplemented by the energy regeneration system that elevated the
intracellular ATP level, the rhodamine uptake was drastically
decreased, which indicates that the function of Pgp was restored.
This treatment group indicates even lower R123 uptake than that
observed in the assay buffer control (significant, P < 0.05). At the
same time, it is noteworthy that the energy regeneration system
produced higher ATP intracellular levels than the levels observed
in the control cells. Two last treatment groups were included in the
study as the controls. First, dodecylamine alone without P85 added
does not change R123 accumulation or ATP intracellular levels in
MCF-7/ADR cells. Second, the mixture of the dodecylamine and
P85 without extracellular ATP added exhibits exactly the same
effect on R123 accumulation in the cells or ATP intracellular
levels as the block copolymer alone. These controls exclude
the possibility that dodecylamine alone or dodecylamine in
Energy depletion in MDR cells by Pluronic P85 1993
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Figure 6 Relationship between the P85-induced changes in R123
accumulation (filled circles) and ATP levels (empty circles) in MCF-7/ADR
cells. Cells were exposed to treatment solutions for 1.5 hcombination with P85 could be inhibitors of the drug efflux
system. Furthermore, these results suggest that in the case when
the energy supplementation system was used, the observed
restoration of Pgp efflux is due to the presence of ATP rather than
some non-specific perturbations in the membrane structure caused
by dodecylamine. 
In another study, the effects of the energy supplementation system
on R123 accumulation and ATP intracellular levels was evaluated
using the sensitive MCF-7 cell line, which has low levels of the
endogenous Pgp as confirmed in the prior study using the Western
blot analysis (Figure 2). As is seen in Figure 7A exposure of these
cells to 0.1% P85 did not affect either R123 accumulation or intra-
cellular ATP levels. When these cells were exposed to the energy
supplementation system, the ATP levels were substantially
increased. However, the transport of R123 in the sensitive MCF-7
cells remained unchanged. This study reinforces the conclusion that
P85 and/or dodecylamine have no effect on permeability of the cell
membrane in non-MDR cells. Furthermore, the increased absorp-
tion of the R123 probe in the MDR cells is attributable to the effects
of the block copolymer on the Pgp efflux system, rather than to non-
specific alterations in membrane permeability of the probe. 
The final experiment reported in this section examined whether
energy supplementation could affect the Pgp efflux system in the
MDR1-transfected cell line, LLC-MDR1. As is seen from the data
presented in Table 6, the effect of the energy supplementation
system in these cells is very similar to the effect of this system in
MCF-7ADR cells described earlier. Indeed, inhibition of Pgp is
observed in these cells following their exposure to 0.1% P85.
However, in the presence of the dodecylamine and extracellular
ATP, the Pgp efflux is restored. No changes in the R123 accumula-
tion were observed when cells were treated with the dodecylamine
alone, which once again confirms that there were no inhibitory
effects of dodecylamine on MDR1. 
Effect of P85 on Pgp ATPase activity 
The effects of P85 on the Pgp ATPase activity were evaluated using
isolated membranes containing human Pgp by assaying the liber-
ated inorganic phosphate (Druekes et al, 1995). The treatment solu-
tions included the copolymer-free buffer control and solutions
containing various concentrations of P85. An additional treatment
group in which the Pgp substrate, verapamil, was added to either
copolymer-free buffer or P85 solutions was also evaluated. The
purpose of including the verapamil groups was to determine
whether binding of a specific substrate with Pgp could modulate
the effects of P85 on Pgp ATPase activity. As seen in Table 7, P85
induced dramatic decreases in Pgp ATPase activity compared to the
copolymer-free control. This inhibitory effect was observed at
concentrations of P85 as low as 0.001% as well as at the higher
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Figure 7 Intracellular ATP levels (empty bars) and R123 accumulation
(filled bars) modulated by various agents in (A) MCF-7/ADR cells and
(B) MCF-7 cells. ATP levels (means + SEM, n = 4) were determined after
exposure of the cells for 1.5 h to the following treatment solutions: 
(1) copolymer-free media, (2) P85 (0.1%), (3) P85 (0.1%) in the presence of
extracellular ATP (50 µ M) and dodecylamine (10–5 M), (4) P85 (0.1%) and
dodecylamine (10–5 M) and (5) dodecylamine (10–5 M). For R123
accumulation studies the same treatment solutions also contained 3.2 µ M of
the probe. 
Table 6 Effects of P85, extracellular ATP and dodecylamine on R123
accumulation in monolayer of LLC-MDR1 cells 
Treatment groups R123 accumulation 
(nmol/mg prot) 
Assay buffer 0.090 ± 0.003 
P85 (0.1%) 0.32 ± 0.02 
0.1% P85, 50 µ M ATP and 10–5 M dodecylamine 0.080 ± 0.001 
10–5 M dodecylamine 0.10 ± 0.01 
Table 7 Effect of P85 on Pgp ATPase activity in isolated membranes
containing human Pgp 
Concentration Pgp ATPase activity, nmol/mg prot × mina
of P85 (% wt.)
In the absence  In the presence 
of vinblastine of vinblastine 
0 9.40 ± 0.40 19.50 ± 0.25 
0.001 1.02 ± 0.05 3.21 ± 0.11 
0.01 0.64 ± 0.02 1.76 ± 0.07 
0.1 1.34 ± 0.05 0.32 ± 0.02 
1 4.22 ± 0.15 3.42 ± 0.12 
aMean ± SEM (n = 4).concentrations examined (up to 1%). Furthermore, the inhibitory
effect of P85 was observed in the presence of verapamil at all block
copolymer concentrations examined (0.001–1%). Verapamil alone
in the absence of the block copolymer induced a significant
increase in Pgp ATPase activity. This effect is believed to be due to
the binding of verapamil in the active centre of Pgp (Shepard et al,
1998; Rebbeor and Senior, 1998). Furthermore, it is noteworthy
that both in the presence and absence of verapamil, the Pgp ATPase
activity was in part restored at 1% P85. In these treatment groups,
the Pgp ATPase activity reached ca. 40–45% of that observed in the
verapamil- and P85-free controls. Therefore, this study suggested
that P85 significantly decreases in Pgp ATPase activity, over-
coming the effect of verapamil activation of the Pgp efflux system. 
DISCUSSION 
The key observation that Pluronic block copolymer reverse MDR
was published previously (Alakhov et al, 1996; Venne et al, 1996),
and that the Pluronic-based formulation of doxorubicin is under-
going clinical trial now. However the mechanisms of the effects of
Pluronic copolymers in MDR cells not are completely understood.
This paper provides key insight into these mechanisms and for the
first time relates it to a selective energy depletion induced by
Pluronic in resistant cells. 
Exposure of resistant and sensitive cells to different doses of
P85 resulted in a transient energy depletion, which was reversed
when the block copolymer was removed. The resistant cells were
much more responsive to P85, exhibiting profound decreases in
ATP levels at 100 times’ lower concentration of the block
copolymer compared to the sensitive cells. The observed transient
energy depletion, in the absence of antineoplastic agent, was not
accompanied by observable toxicity in the cells since Pluronic
alone did not exert any significant cytotoxic effect in either the
resistant or the sensitive cells. However, if the antineoplastic
agent, doxorubicin, was introduced concurrently with the block
copolymer, the cytotoxic effect of doxorubicin was significantly
increased compared to the drug alone. 
Overall, based upon this study, the sensitization effect of the
block copolymer in resistant cells appears to be related to energy
depletion. First, there is a clear correlation between the potentia-
tion of the cytotoxicity of doxorubicin and ATP depletion induced
by the block copolymer observed in both drug-selected and trans-
fected MDR cells. Second, ATP depletion by the metabolic
inhibitors is also accompanied by the potentiation of the cytotoxic
activity in the MDR cells. Finally, this work demonstrates that
treatment of the cells with the energy-supplementation system
reverses the sensitization of the MDR cells by Pluronic. 
Previous work has demonstrated that Pluronic affects multiple
mechanisms of drug resistance in MDR cells. There is over-
whelming evidence to suggest that Pluronic block copolymers
inhibit Pgp efflux systems in Pgp-expressing cells (Venne et al,
1996; Batrakova et al, 1998; 1999). No alteration in drug uptake in
the presence of Pluronic was observed with non-MDR cells. This
provides additional support for the specific effects of the
copolymer on the Pgp transport system. This conclusion is consis-
tent with the recent studies by Evers et al (2000) and Batrakova
et al (2001), demonstrating that Pluronic block copolymers (L61,
P85) have pronounced effects, increasing accumulation and perme-
ability of various Pgp-dependent drugs in MDR1-transfected cells,
which overexpress Pgp. In addition to the effects on the Pgp efflux
system, Pluronic block copolymer can affect other drug-resistant
mechanisms present in MDR cells. For example, a previous study
by Venne et al (1996) demonstrated that exposure of the MDR
cells to Pluronic block copolymers abolishes sequestration of
drugs in the cytoplasmic compartments. 
Both the drug-efflux systems and the drug-sequestration mecha-
nisms in MDR cells are ATP dependent. This work suggests that
there is a clear relationship between the energy depletion and Pgp
inhibition induced by the block copolymer: the lower the ATP
level, the less active the Pgp-efflux system becomes. Furthermore,
treatment of the cells with the energy-supplementation system,
which restores ATP levels within the cells, also reverses the effect
of P85 on Pgp. It is tempting to suggest that the energy depletion
is the sole reason for inhibition of various ATP-dependent drug
resistance mechanisms in MDR cells. However, using isolated
membranes expressing Pgp, this study also demonstrates that P85
can inhibit the Pgp ATPase activity. Therefore, the block
copolymer may have a 2-fold effect in MDR cells – one through
ATP depletion and another through inhibition of the Pgp ATPase
activity; both have a combined result of potent inhibition of Pgp. 
Previous reports have suggested that certain Pluronic block
copolymers, including P85, studied in this work, can affect metabo-
lism in cells. For example, decreased ATP levels were observed
following exposure to P85, in the Jurkat T-cell lymphoma (Slepnev
et al, 1992). Furthermore, a study by Kirillova et al (1993)
suggested that P85 inhibits respiration, both in isolated mitochon-
dria and in whole cells. One important observation made in the
present work is that MDR cells are much more responsive to
Pluronic than non-MDR cells. The reasons for such a remarkable
selectivity of Pluronic block copolymers with respect to MDR
cells are not completely understood. One hypothesis is that the
high rates of energy consumption by the drug efflux pumps,
combined with Pluronic-induced inhibition of respiration, deter-
mine the responsiveness of the resistant cells to the block
copolymer. Under conditions in which the respiration necessary
for ATP synthesis is inhibited, the high rates of ATPase activity by
the drug efflux pumps (and possibly, some other energy-depen-
dent mechanisms) could result in a rapid exhaustion of the intra-
cellular ATP pools in the resistant cells. Alternatively, cells that
do not exhibit these resistance mechanisms would appear to be
less responsive to inhibition of respiration and would not exhibit
energy depletion, at least to the extent observed in the resistant
cells. Such a hypothesis is in line with the earlier observation that
resistant cells have an increased glucose utilization rate compared
to sensitive cells (Kaplan et al, 1991). Furthermore, the toxicity of
2-deoxyglucose, a glucose antimetabolite, was found to be consis-
tently higher in MDR cells than in the parental drug-sensitive
lines (Kaplan et al, 1990; 1991). This study directly demonstrates
that metabolic inhibitors deplete ATP in the resistant cells more
than in the sensitive cells. The extent of the selectivity of P85 with
respect to MDR cells is the same of even greater than that of the
inhibitor of glycolysis, 2-deoxyglucose. Furthermore, P85 is
significantly more selective than the inhibitors of respiration,
rotenone and sodium aside. However, the present study also
suggested that P85 significantly inhibits ATPase activity of Pgp in
isolated cell membranes. Since Pgp is one of the major ATPases
overexpressed in MDR cells and the fact that Pluronic inhibits
this activity, it makes the high energy consumption in MDR cells
a less likely cause for the block copolymer selectivity in these
cells. An alternative hypothesis would be that for some reason the
metabolic processes in MDR cells are more sensitive to inhibition
with Pluronic than the metabolic processes in non-MDR cells.
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following exposure of MDR cells to the block copolymer. It also
has to be emphasized that overexpression of Pgp is not the only
reason for the appearance of the MDR phenotype. The MDR cells
frequently express other efflux proteins, such as MRP (Zaman
et al, 1995; Hayes and Pulford 1995), have high levels of H+-
ATPase (Benderra et al, 1998) and exhibit the activated glutathione/
glutathione S-transferase detoxification system (Altan et al, 1998).
These and possibly other factors could impose high energy require-
ments in MDR cells and collectively contribute to the elevated
responsiveness of these cells to Pluronic. The high responsiveness
to P85 of the cell lines, which have relatively low levels of Pgp
expression, HUVECs and Caco-2 may be one indication of the
possible involvement of alternative mechanisms in the energy
depletion. 
In any case, it appears that energy depletion is an Achilles heel
of MDR cells, turning the high energy requirements imposed on
these cells by drug resistance mechanisms into a vulnerability
resulting in elevated cytotoxic effects. While a number of experi-
mental and clinical approaches have been studied to overcome
MDR, including the use of MDR chemosensitizers, the appear-
ance of several distinct transporters in resistant cells may limit
the success of those agents, which target a single drug efflux
pump. Furthermore, the combination of several independent
mechanisms of drug resistance might complicate chemotherapy
and reinforces the need for development of novel drugs and drug,
formulations effective against drug-resistant cancers. It has
long been suggested that a broadly successful strategy for killing
drug-resistant cancer cells could be based on selective energy
depletion in these cells, since many mechanisms of drug resis-
tance are energy dependent (Mansouri et al, 1992). However, no
study so far has reported such a significant decrease in ATP
levels, which is observed selectively in MDR-expressing cells.
Therefore, the finding of energy-depleting effects of Pluronic
block copolymers, in combination with their very high sensitiza-
tion effects and ability to inhibit multiple mechanisms of drug
resistance in MDR cells is of considerable theoretical and
practical significance. 
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